Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
sgtr5MukGLaArHAT